You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Bruins Live

0

3

1st Prd 0:03

Aveo stock rebounds a bit after big plunge

The FDA’s decision could delay the drug’s approval.

Reuters/File 2012

The FDA’s decision could delay the drug’s approval.

Continue reading below

It was hardly a rebound, but Aveo Pharmaceuticals Inc. gained some ground Wednesday, a day after its stock plummeted 31.3 percent as the Food and Drug Administration said it may require another clinical trial of the Cambridge company’s drug for advanced renal cell carcinoma, tivozanib. The FDA had been scheduled to decide by July 28 whether to approve the drug but raised questions about whether it improves survival rates more than a drug that’s already available.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com